000 04219nam a22004935i 4500
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_1http://viaf.org/viaf/148105729
_9106996
999 _c107983
_d107983
_x1
001 107983
003 DE-He213
005 20230102113329.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 180319s2018 gw | s |||| 0|eng d
020 _a9783319724164
024 7 _a10.1007/978-3-319-72416-4
_2doi
040 _bspa
_dES-MaUEC
050 4 _aRM302 2018 EB
090 4 _aRS380
090 4 _aRS190-210
245 0 0 _aDrug Interactions in Infectious Diseases: Antimicrobial Drug Interactions
_cedited by Manjunath P. Pai, Jennifer J. Kiser, Paul O. Gubbins, Keith A. Rodvold.
250 _a4th ed. 2018.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Humana Press
_c2018.
300 _a1 recurso en línea ( XVI, 565 páginas 2 ilustraciones, 1 ilustraciones a color)
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 1 _aInfectious Disease
490 _aMedicine (Springer-11650)
505 0 _aBeta-Lactam Antibiotics -- Macrolides, Azalides, and Ketolides -- Quinolones -- Glycopeptides, Lipopeptides, and Lipoglycopeptides -- Miscellaneous Antibiotics -- Drugs for Tuberculosis -- Drug Interactions in HIV: Protease and Integrase Inhibitors -- Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors -- Hepatitis B and Hepatitis C Antiviral Agents -- Drug Interactions of Non-HIV Antiviral Agents -- Antifungal Agents -- Antimalarial Agents -- Antiprotozoal and Anthelminthic Agents.
520 _aThe 4th edition of Drug Interactions in Infectious Diseases is being split into two separate volumes - "Mechanisms and Models of Drug Interactions" and "Antimicrobial Drug Interactions". This volume, "Antimicrobial Drug Interactions," delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
988 _aSpringer_Medicine_2018
650 7 _2embne
_9169576
_aMedicamentos
_xInteracción
650 7 _2embne
_aEnfermedades infecciosas
_9138404
700 1 _aPai, Manjunath P
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_1http://viaf.org/viaf/180137727
700 1 _aKiser, Jennifer J
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_1http://viaf.org/viaf/197154739959452992553
700 1 _aGubbins, Paul O
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_1http://viaf.org/viaf/237154739968152992855
700 1 _aRodvold, Keith A
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_1http://viaf.org/viaf/70342267
776 0 8 _iPrinted edition:
_z9783319724157
776 0 8 _iPrinted edition:
_z9783319724171
776 0 8 _iPrinted edition:
_z9783030101978
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-72416-4
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _aSI
_b07/2019
_cm
_dz
_feng
_ggw
_h0
_ejf
_zSI